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Abstract
Parkinson’s disease (PD) is a common age-related neurodegenerative disease and it is critical to develop models which
recapitulate the pathogenic process including the effect of the ageing process. Although the pathogenesis of sporadic PD is
unknown, the identification of the mendelian genetic factor PINK1 has provided new mechanistic insights. In order to
investigate the role of PINK1 in Parkinson’s disease, we studied PINK1 loss of function in human and primary mouse
neurons. Using RNAi, we created stable PINK1 knockdown in human dopaminergic neurons differentiated from foetal
ventral mesencephalon stem cells, as well as in an immortalised human neuroblastoma cell line. We sought to validate our
findings in primary neurons derived from a transgenic PINK1 knockout mouse. For the first time we demonstrate an age
dependent neurodegenerative phenotype in human and mouse neurons. PINK1 deficiency leads to reduced long-term
viability in human neurons, which die via the mitochondrial apoptosis pathway. Human neurons lacking PINK1 demonstrate
features of marked oxidative stress with widespread mitochondrial dysfunction and abnormal mitochondrial morphology.
We report that PINK1 plays a neuroprotective role in the mitochondria of mammalian neurons, especially against stress such
as staurosporine. In addition we provide evidence that cellular compensatory mechanisms such as mitochondrial biogenesis
and upregulation of lysosomal degradation pathways occur in PINK1 deficiency. The phenotypic effects of PINK1 loss-of-
function described here in mammalian neurons provides mechanistic insight into the age-related degeneration of nigral
dopaminergic neurons seen in PD.
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Introduction
Parkinson’s disease (PD) is the most common neurodegenerative
motor disorder in the Western world. The disease is characterised
clinically by resting tremor, rigidity and slowness of movement
(bradykinesia) with symptoms being partially alleviated by
administration of exogenous dopamine (L-dopa). Upon neuro-
pathological examination, the brains of patients with PD show
marked loss of pigmented dopaminergic (DAergic) neurons of the
substantia nigra pars compacta (SNpc), and other brain regions. In
addition, surviving neurons frequently contain Lewy bodies (LBs)
which are intracytoplasmic proteinaceous inclusions, predomi-
nantly composed of aggregated a-synuclein. PD is a progressive,
incurable and age-related disease, affecting ,1.8% individuals by
the age of 65 years [1]. The majority (.85%) of PD cases are
sporadic, and the underlying molecular causes unknown. Insight
into the mechanisms of PD pathogenesis has come from the
identification of mutations in genes associated principally with
familial forms of PD. Inherited forms of PD have been linked to
mutations in six different genes with seemingly diverse functions.
These encode the synaptic protein a-synuclein [2]; an E3 ubiquitin
ligase, parkin [3]; a putative antioxidant chaperone, DJ-1 [4], a
mitochondrial kinase, (PTEN)-induced kinase 1 (PINK1) [5], a
mitochondrial serine protease, OMI/HTRA2 [6], and leucine-
rich repeat kinase 2 (LRRK2) [7]. Discovery of these genes have
strongly implicated certain cellular processes in the etiology of
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and impairment of the ubiquitin proteasome system, mitochon-
drial dysfunction, oxidative stress and protein phosphorylation [8].
The role of mitochondrial dysfunction in PD has been suggested
since the original discovery that the complex I inhibitor 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) caused the develop-
ment of PD in recreational drug users [9]. Other complex I
inhibitors including rotenone and paraquat have similarly been
found to cause PD–like symptoms in rodent models [10].
Inhibition of the mitochondrial respiratory chain is known to
increase the generation of free radicals leading to cellular oxidative
stress within cells [11]. Concordantly, evidence of impaired
complex I activity has been reported in post-mortem PD brain
tissue with an increase in markers of oxidative stress [12]. However
the most convincing evidence to date has been the characterisation
of genes mutated in familial PD with putative functional roles
within mitochondria. Both PINK1 and Omi/HtrA2 have
predicted mitochondrial targeting sequences and appear to exhibit
protective functions within this organelle [5,6,13]. Parkin, DJ-1, a-
synuclein and LRRK2 have also been shown to associate with the
mitochondrion or impact upon its function, but the mechanisms
involved remain unclear [14–17].
PINK1 is a highly conserved 581 amino acid protein with a
catalytic serine/threonine kinase domain with close sequence
homology to CAMK1 [5]. Several studies have demonstrated that
recombinant PINK1 can undergo autophosphorylation as well as
phosphorylate generic substrates in vitro [18–20]. It has a predicted
N-terminal mitochondrial targeting motif and a significant
proportion has been localised to both the inner and outer
mitochondrial membranes [5,19,21]. Full length PINK1 pre-
protein (,63 kDa) can also be cleaved to a ‘mature’ form (54 kDa)
by an unknown protease [21,22]. PINK1 mRNA is ubiquitously
expressed in human tissues, with highest expression in heart,
muscle and testes [23]. It is uniformly expressed in mammalian
brain, with highest expression levels found within the cell bodies of
neurons and glia [21,24].
Homozygous and compound heterozygous mutations in the
PINK1 gene locus are known to cause PARK6 familial
Parkinsonism, which is indistinguishable from idiopathic PD apart
from an earlier age of onset [5]. To date there are no
neuropathological data from any individual affected with a
homozygous mutation in the PINK1 gene. However, brains of
patients with PINK1 heterozygote mutations display the typical
pathological hallmarks of idiopathic PD [21]. The prevalence of
PINK1 mutations in autosomal recessive early onset PD range
from 0-15%, depending on the patient series analysed [25–27].
This suggests that PINK1 is the second most common causative
gene in early onset PD after parkin [25]. The vast majority of
pathogenic mutations in PINK1 gene are located within the kinase
domain and include nonsense, missense and deletion mutations
which are predicted to either reduce or obliterate kinase activity
[20]. Accordingly, reduced kinase activity has been demonstrated
in vitro for the pathogenic mutations G309D, L437P, G386A and
G409V [18,20]. The most common mutation, a C1366T
transition, reportedly triggers nonsense-mediated mRNA decay,
resulting in a 80–90% reduction in transcript levels in tissues from
homozygous patients [28]. Taken together, these findings suggest
that PARK6 parkinsonism results from a loss-of-function of the
PINK1 protein.
Valid animal models of PINK1 parkinsonism should recapitu-
late the motor symptoms seen in patients as well as the underlying
nigrostriatal deficiencies and neuropathological findings. Howev-
er, no motor impairments or other non-motor parkinsonian
symptoms have been reported in PINK1 loss-of-function mouse
models to date [29,30]. In contrast, Drosophila models of PINK1
deficiency have given us closer insights into the molecular
mechanisms involved [31–34]. Motor deficits include abnormal
wing posture, rigidity, flight impairment and reduced climbing
ability [31,32,34]. Moreover, some of these motor phenotypes
were found to be progressive with age [32,34] and showed partial
but significant decreases (,10%) in the numbers of dopaminergic
neurons in certain key clusters within the fly brain [32–34].
Ultrastructurally, muscle fibres contained vacuolated, swollen and
dysmorphic mitochondria, with disorganised christae which was
also seen in surviving dopaminergic neurons [32]. Both ATP
production and resistance to oxidative stressors was compromised
in PINK1 deficient flies. Although fly models of PINK1 loss-of-
function have recapitulated mitochondrial dysfunction and age-
related neuronal death, the actual mechanisms remain unclear.
Cellular pathogenesis of PINK1 loss of function in PD
The molecular mechanism by which PINK1 operates in the
mitochondria is undefined, but the first in vitro cellular studies of
PINK1 loss-of-function implicated a role for the kinase in
maintenance of mitochondrial membrane potential and preven-
tion of stress-induced apoptosis [5]. Over-expression of wild-type
(but not pathogenic variants) in tumour cell lines was subsequently
shown to prevent release of cytochrome c from mitochondria and
caspase-3 activation during stress [5,35,36]. In contrast, depletion
of PINK1 from cells using transient RNA interference (RNAi) was
shown to increase the rate of basal and stress-induced apoptosis
[37,38]. A novel pathway for PINK1 has recently been proposed
following the identification of the serine protease HtrA2/Omi as a
PINK1 interactor. Mutations in HtrA2 are a susceptibility factor
for PD (PARK13 locus) and loss of function models in mice display
a neurodegenerative phenotype resembling parkinsonism. Phos-
phorylation of HtrA2 at Ser142 is dependent on PINK1 and the
phosphorylated form demonstrates increased protease activity and
enhanced protective effect in cells upon stress [13].
To date the majority of studies of PINK1 function come from
non-mammalian models, or non-neuronal in vitro cell models
cultured over relatively short periods of time. Whilst yielding
important insights they do not recapitulate the human disease, that
is, in ageing human dopaminergic neurons. To address this issue,
we created a unique model of PINK1 loss-of-function, in a human
neural stem cell (NSC) line that is able to differentiate into
functional dopaminergic neurons [39]. This novel cellular system
recapitulates the key features of PD namely dysfunction and death
in ageing midbrain neurons. In addition, we utilised primary
mouse neurons taken from mice and a widely used human
dopaminergic neuroblastoma cell line (SHSY5Y), which allowed
cross-validation in three complementary cellular systems. We
report the spatio-temporal expression of PINK1 in human
dopaminergic neurons, and the effects of PINK1 deficiency
including chronic mitochondrial dysfunction, an increase in
oxidative stress, and lysosomal pathology. These phenotypic
effects may all contribute to the marked decrease in long term
viability of PINK1 deficient neurons and enhanced basal and
stress-induced caspase-3 activation leading to apoptosis. Our
findings give new insights into the underlying dysfunction of
human dopaminergic neurons in PINK1 parkinsonism and
sporadic PD, by utilising a truly representative in vitro cellular
model of the disease.
Materials and Methods
All chemicals and reagents were obtained from Sigma or
Invitrogen unless otherwise stated.
PINK1 Deficiency
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The PINK1 deficient mice were generated by Lexicon Genetics
Inc. (The Woodlands, Texas, USA). See supplementary
Methods S1 online.
Cell culture
Human NSCs (ReNcell VM NSCs) were provided by
ReNeuron Ltd. Derivation of the line from human fetal ventral
mesencephalon and maintenance has previously been described
[39]. Briefly, NSCs were grown in laminin coated flasks/plates
(Trevigen; 20 mg/ml in DMEM:F-12) in B27 medium (DMEM:F-
12 with 1X B27 supplement, 2mM Glutamine, 10 Units/ml
heparin and 50 mg/ml gentamycin) containing growth factors
human bFGF [10ng/ml, Peprotech] and human EGF [20ng/ml,
Peprotech]. Media on NSCs was changed every 48 hours.
Differentiation was carried out using either the stdD or preD
method [39]. For StdD differentiation, NSCs were seeded at
30,000 cells/cm on laminin and expanded to 80% confluency in
B27 medium containing growth factors (+GFs). Differentiation was
initiated by changing to Differentiation medium: B27 medium
without growth factors or antibiotics and supplemented with 1mM
dibutyrl-cAMP (Calbiochem) and 2ng/ml GDNF (Peprotech).
Media was not changed for the first 5 days, then after that every 3–
4 days. For the PreD method, NSCs were trypsinised and plated
out at 30,000 cells/cm onto uncoated plates in B27 medium+GFs.
NSCs were left to form aggregates for 7 days without a media
change. Aggregates were then transferred to laminin-coated plates
of equivalent surface area in B27 medium+GFs for 3–4 days to
allow cells to disperse and reach 90% confluency. Differentiation
was initiated and continued as for StdD protocol. ReNcell VM
NSCs are referred to as human NSCs and ReNcell VM
differentiated neurons are referred to as human midbrain neurons.
SHSY5Y human neuroblastoma cells were maintained as
described (Muqit et al 2006).
For primary mouse cortical cultures, embryos were taken at
gestational stage E16–E17. Animal husbandry and experimental
procedures were performed in full compliance with the United
Kingdom Animal (Scientific Procedures) Act of 1986. Cultures
were set up as described in Supplementary Methods S1. Neurons
were cultured in 96 well plates in maintenance medium
[Neurobasal medium, 2% (v/v) B27 supplement, 2 mM gluta-
mine, 100 I.U./ml penicillin and 100 I.U./ml streptomycin and
0.45% (v/v) D2(+) glucose]. Tissue harvested for biochemistry
was snap frozen on dry ice and stored at 270uC. Embryos were
obtained by crossing two heterozygote animals resulting in a
mixture of F1 genotypes; genotyping is described in Supplemen-
tary Methods S1.
Apoptosis and cell death/viability Assays
Annexin V PE binding. For analysis of apoptosis in NSCs
and SHSY5Y cells, FACS was used to determine AnnexinV-FITC
binding in conjunction with 7-Amino actiniomycin (7AAD) uptake
according to manufacturer’s instructions (BD Pharmingen). Briefly
SHSY5Y cells were seeded at 600,000 cells per well of a 6 well
plate, in triplicate, and incubated overnight in SHSY5Y medium
containing DMSO or 60 nM STS (Calbiochem). Human NSCs
were seeded in triplicate in 6 well plates at 200,000 per well. The
following day NSCs were incubated in media containing DMSO
only (1:1000) or STS (50 nM) for 3 h at 37uC prior to processing.
A total of 10,000 cells were analysed for cell death by FACS
Calibur (Beckton Dickenson, CA) with the Cell Quest software.
Multiparameter Cytoxicity Assay. We used the
Multiparameter Cytotoxicity 1 HCS Reagent kit (Cellomics) for
the assessment of overall culture viability using multiple cell
parameters in differentiated human and mouse neurons at
different time points. The assay was carried out according to the
manufacturer’s instructions. Plates were analysed with an
ArrayScan HCS reader and Cytotoxicity Indices (CIs) calculated
using the Multiparameter Cytotoxicity 1 BioApplication Software
(Cellomics). A full explanation of this algorithm is provided on the
supplier’s website: http://www.cellomics.com/content/menu/
MP_Cytotoxicity/. Briefly, nuclear size, morphology and cell
density measurements are made on nuclei automatically identified
in fluorescence channel 1. The BioApplication then measures
nuclear intensity in channel 2 and the intensity of lysosomal stain in
the cytoplasmic region in channel 3. Upper and lower thresholds are
automatically set for nuclear morphology/size, cell membrane
permeability and lysosomal mass from user-configurable reference
wells (control or wild type neurons). The percentage (indices) of cells
in each well that are outside of these thresholds is ascertained. The
Cytotoxicity Index is the maximal of nuclear morphology index,
membrane permeability index, lysosomal mass index and cell
density index, for each well. A mean CI is calculated based on three
replicate wells per clone/genotype.
Counting apoptotic nuclei. Human neurons were
differentiated using the Pre-D protocol on poly-L-lysine glass
coverslips (Biocoat) pre-coated in laminin. At 5 and 43 days
differentiation (dd), cultures were incubated with either 1 mM STS
or vehicle (DMSO) for 3 h before being fixed. Immunostaining was
undertaken using dual labeling with anti-bIII tubulin, anti-TH and
Hoechst 33342 as described [39]. Images were taken using an
Axioplan Imaging microscope (Zeiss) using a 25X objective (see
below).Atleast50adherentneuronsperculturewereexamined and
their nuclei scored as normal or pyknotic (fragmented/condensed)
by a blinded observer. In addition, images from 5–10 non-
overlapping fields of view were taken per culture using Axioplan
software.Imageswereprinted and thepercentageofpyknoticversus
normal neuronal nuclei were scored.
Cytochrome C release. Release of cytochrome c from
mitochondria in SHSY5Y cells was carried out using the
Apoptosis Detection Kit (MitoSciences) according to
manufacturer’s instructions.
SDS-PAGE and immunoblot analysis
For details see supplementary Methods S1 online. Cells
were lysed by the direct addition of sample buffer and protein
lysates separated on 10% or 16% Tris-Glycine mini gels by SDS-
PAGE, before transfer onto nitrocellulose membranes. Mem-
branes were incubated in non-fat milk in PBS with 0.1% Tween-
20 (PBST) then with primary antibodies (see Table S1).
Membranes were washed then incubated with HRP-conjugated
secondary antibodies (Dako). Membranes were incubated with
SuperSignal West Pico Chemiluminescent Substrate (Pierce) and
bands detected with x-ray films (BioMax). Equivalent protein
loading was confirmed by stripping membranes and re-probing
with anti-b-actin antibody. Band densitometry was performed
using Quantity One 4.6.6 software (BioRad).
RNA extraction, cDNA synthesis and RT-PCR
Total RNA was isolated using TRIzol reagent and cDNA
synthesised using random primers according to manufacturer’s
instructions. cDNA was diluted 1:5 in water prior to PCR. All
TaqMan Real Time PCR reactions were performed using using
FAM-labelled PINK1 probe and VIC/TAMRA-dye labelled
Endogenous control Human RPLPO or GAPDH (Applied
Biosystems). PCR was performed using the ABI PRISM 7700
Sequence Detection System. Gene expression was calculated using
the 2
-ddCT method [40].
PINK1 Deficiency
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Optimal short hairpin RNA 19mer sequences targeted to human
PINK1 (NM_032409) were determined using the Dharmacon
siDESIGN Center (http://www.dharmacon.com). The 19mers
with the highest predicted efficacy (scores $7) were selected. Single
stranded 64mers were obtained from Operon. The forward and
reverse sequencesaredetailed insupplementary Methods S1online.
Oligomers were annealed and ligated into pSUPER.retro.puro
(PSR) mammalian expression vector (Oligoengine) according to the
manufacturer’s protocol. Ligation mixtures were used to transform
JS4 competent E.coli. Maxipreps of successfully ligated vectors were
prepared using a Quaigen kit and sequenced. Vectors were
packaged into retroviral particles using y-NX-Ampho cells. Viral
supernatant harvested from transfected cells was sterile filtered and
stored at -70uC until required.
Production of stable cell lines
Early passage NSCs were infected with viral supernatant
containing PSR vector, PSR containing shRNA sequences (supple-
mentary Methods S1 online). When confluent, NSCs were split and
transduced cells selected for using Puromycin (1 ug/ml). Cell colonies
were picked and further propagated before screening by RT-PCR.
Immunofluorescence and image acquisition
Immunostaining of coverslips and 96 well plates was carried out
as described previously [39]. Details of all antibodies are available
in supplementary data online (Table S1). For live dye staining of
organelles, Mitotracker Red CMXRos or Lysotracker was used
according to manufacturer’s instructions. Coverslips were mount-
ed onto slides using fluorescent mounting medium (Dakocytoma-
tion). Non-confocal images were obtained using an Axioplan 2
MOT microscope (Zeiss) with filters for FITC, Rhodamine and
DAPI and Plan Neofluar 25x/0.8 Ph2 objective at RT. Images
were taken using an AxioCam MRm (Zeiss) camera and
controlled using the Axiovision Control software. Alternatively,
images were obtained using an LSM510 META confocal
microscopy system (Zeiss) equipped with ‘‘plan-Apochromat’’
63x/1.40 Oil DIC objective at RT controlled by Zeiss LSM
software. Fluorescence was recorded at 488nm using 30mW Ar-
laser for excitation or at 543 nm using 1mW HeNE laser for
excitation. Zeiss Immersol was used as imaging medium. For
counting of tyrosine hydroxylase (TH) and neurofilament (NF)
positive cells, the Cellomics ArrayScan HCS reader was used
and images from 30 fields of view per well were analysed using the
Target Activation BioApplication software.
Transmission Electron Microscopy
Human NSCs were plated on 13mm Thermanox coverslips
coated with laminin. When confluent, NSCs were differentiated
using the SD/DA protocol for 47 dd and fixed using 3%
glutaraldehyde in 0.1 M sodium cacodylate buffer and 5 mM
CaCl2, pH 7.4. Specimens were dehydrated through a graded
series of Analar Ethanol (70% 90% 100%). Cells were embedded
in araldite resin mixture and sectioned using a Richert Ultracut S
microtome. Sections were stained using 25% Uranyl acetate in
methanol and Reynold’s Lead Citrate and images were taken on a
Philips CM10 transmission electron microscope at 3800X and
9800X magnification. Images were taken using the KeenView
system from SIS, resized and annotated in Adobe Photoshop.
Live cell imaging
Live cell imaging was performed as described previously [41].
See supplementary Methods S1 online. Briefly, cells were
bathed at RT in a HEPES-buffered salt solution (HBSS)
containing (mM): 156 NaCl, 3 KCl, 2MgSO4, 1.25 KH2PO4,2
CaCl2, 10 glucose and 10 HEPES, pH 7.35. For Dym
measurements, 25 nM TMRM was included and cells were
incubated for 45 min. Z-stacks of .20 neurons per clone were
obtained using a Zeiss LSM confocal microscope. Images were
analysed using Lucida 6 software. For ROS measurements,
MitoSOX (10 mM) was loaded for 10 min followed by washing.
Dihydroethidium (HEt, 10 mM) was present in all solutions
throughout the experiments. Confocal images were obtained
using a Zeiss 510 uv-vis CLSM equipped with a META detection
system and a 40x oil immersion objective. HEt or MitoSOX were
excited using the 543 nm laser line and fluorescence measured
using a 560nm longpass filter.
Measurement of total and reduced glutathione.
See supplementary Methods S1 online
Citrate synthase activities
Statistical analyses
All experiments were performed with three different cell clones,
in triplicate. Data were analysed by parametric Student T-tests and
significance expressed as follows *P,0.05, **P,0.01, ***P,0.001
unless otherwise stated. For all graphs bars represent mean6SEM.
Online supplementary material
Generation of PINK1 knockout mice
Primary embryonic mouse cultures
Table S1 Antibodies
SDS-PAGE and immunoblotting
Production of stable cell lines
Measurement of total and reduced glutathione
Live cell imaging
ETC activities
Results
PINK1 is up-regulated following differentiation of human
NSCs to dopaminergic neurons
We first sought to validate the use of the human NSC model,
differentiated to human midbrain neurons, as a useful model to test
PINK1 function. RT-PCR confirmed upregulation of expression of
a range of dopaminergic neuronal markers (tyrosine hydroxylase,
TH, dopamine transporter, DAT) upon differentiation of NSCs to
human neurons (Figure S1A). In addition there was an upregula-
tion of the expression of markers Lmx1a and Nurr1, both of which
are involved in committing precursor cells to dopaminergic
differentiation. Furthermore we demonstrated that the human
neurons expressing TH, also expressed PINK1. PINK1 expression
is highest in mature neurons as demonstrated by immunofluores-
cence (Figure 1A). PINK1 was detected by RT-PCR in human
NSCs (Figure 1C). Moreover, PINK1 expression was found to
increase up to ,100 fold following differentiation to neurons,
(Figure 1C) suggesting a physiological role of PINK1 within
differentiated human neurons. This high level of PINK1 expression
in differentiated human DAergic neurons validated the use of this
model in examining the effects of loss of PINK1 function.
RNAi-mediated knockdown of PINK1 mRNA in human
cell lines
Using retroviral mediated PINK1 shRNA expression, levels of
PINK1 knockdown ranging from 10–90% were achieved. The
efficiency of PINK1 knockdown (PINK1 kd), determined by RT-
PCR, was found to be shRNA sequence specific, with sequence
PINK1 Deficiency
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and the human NSCs. (Figure S1 B). shRNA directed against a
different gene (Lamin AC) did not reduce PINK1 mRNA levels
(see S1B), confirming that this method did not result in non-
specific PINK1 kd. Results shown are normalized for housekeep-
ing gene, LRPO. However RT_PCR for other genes including
two other control genes (b-actin and GAPDH) as well as other PD
genes (parkin and DJ-1) did not show significant alterations in
expression between control and PINK1 kd (data not shown)..
Knockdown of endogenous PINK1 mRNA was maintained after
differentiation as human neurons (Figure 1D) even taking into
account the ,100 fold increase in PINK1 expression described
above. Analysis of protein levels by Western blotting confirmed
reduced levels of protein expression in #1029 clones compared
Figure 1. PINK1 Expression & Up-regulation. A) PINK1 expression in human dopaminergic neurons. Red; PINK1, green; TH, blue; hoescht. B)
Western blot showing endogenous PINK1 protein expression in control (c) and PINK1 kd (with 90% mRNA knockdown) human neuronal lysates after
5 days differentiation. Anti-PINK1 (Novus) was used to detect PINK expression; b-actin levels are shown as loading control. C) Histogram showing
relative fold change in PINK1 mRNA expression levels between NSCs, 5 day differentiation (dd5), 30 day differentiation (dd30). PINK1 expression levels
from pre-immortalised neural stem cells from 8 week old ventral mesencephalon (Midbrain P5) and adult human brain (Human Cb) are shown for
comparison. Values represent mean of three replicate samples6s.e.m. D) Histogram showing expression of PINK1 mRNA in human neurons in four
control (c1-4) and four PINK1 kd (kd1-4) selected clones relative to an endogenous control gene. RQs were normalised to that of c1; values represent
mean of 3 replicate samples6standard error (s.e.m). E) Immunofluorescence images showing dopaminergic cells in control (i) and PINK1 kd (ii)
human neuronal cultures after 5 days differentiation. Red; TH, green; bIII tubulin, blue; Hoecsht.
doi:10.1371/journal.pone.0002455.g001
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PINK1 expression in cultured cortical neurons from the PINK1
knockout mouse model by Western blot (Figure S1D).
PINK1 is not necessary for differentiation of human
neural stem cells to dopaminergic neurons
Human NSC lines, carrying the stable #1029 PINK1 kd
shRNA, does not prevent differentation into human DAergic
neurons as demonstrated by tyrosine hydroxylase (TH) immuno-
staining, following the PreD differentiation protocol (Figure 1E).
No difference in TH expression was found between PINK1 kd
neurons and controls using Western blot (data not shown). The
PreD protocol generates the highest proportion of DAergic
neurons in ReNcell cultures [39]. However, due to the formation
of ‘neuronal aggregates’ in these cultures, accurate quantification
of percentage TH+ neurons is extremely difficult using microsco-
py. In contrast, the StdD protocol gives rise to a monolayer of
neurons, which permits the use of the Cellomics microscope and
BioApplication software to robotically count (cytoplasmic) TH+
neurons. Control or PINK1 kd human neuronal cultures
contained 1–5% TH+ neurons using the StdD protocol. There
was no significant difference in the proportion of TH+ cells in
control or PINK1 kd cells, either as a percentage of total cells or
percentage of total neurons (data not shown).
PINK1 deficiency results in age-related reduction in basal
viability of human and mouse neurons
We then investigated if PINK1 was necessary for the survival of
neurons. Due to the characteristics of the different cell models, we
employed different methods to assess viability and apoptosis.
SHSY5Y cells are proliferative neuroblastoma cells that may be
assessed using flow cytometry for both viability and apoptosis.
Annexin V/PI flow cytometry of PINK1 kd SHSY5Y cells showed
a significant reduction in the number of live cells after 96 h in
culture when compared to control cells (p=0.0263). Furthermore
we observed a concomitant increase in cells undergoing early
apoptosis, as shown by cells expressing annexin V only
(p=0.0023), and cells staining for both PI and annexin V
(p=0.0218) (Figure S2B). To assess the viability of differentiated
human neurons, we employed a cytotoxicity assay for neurons at
days 15, 30, 43 and 52 in culture. Cytotoxicity Indices (CI) for
control and PINK kd cultures were calculated at each time point.
There was no significant difference in basal viability at day 15, but
from days 30 to 52, there was a significant and increasing
difference in the mean CI of PINK1 kd neurons compared to
controls, demonstrating an age-dependent effect of loss-of-PINK1
function (Figure 2A). By 52 days differentiation, the mean CI of
PINK1 kd neurons was ,30% above that of controls (p,0.001).
Using the Cellomics software we examined differences in the
various parameters quantified using the Multiparameter Cytotox-
icity 1 BioApplication Software which are collated into the final CI
readout. These revealed a striking reduction in mean nuclear size
and fluorescence intensity, indicative of apoptosis (Figure 2C,D).
Indeed we found a significant increase in the percentage apoptotic
neurons in aged PINK1 kd cultures compared to controls by
manual counting of pyknotic nuclei (Figure 2F). In addition there
was a significant increase in mean lysosomal mass/pH in aged
PINK1 kd neurons (Figure 2E).
We then sought to confirm these findings using primary
embryonic cortical cultures from PINK1 KO mice (Figure
S2C). Again we found the basal viability of neuronal cultures
lacking PINK1 declined with age with mouse cortical KO neurons
having significantly higher CI than controls by later time points
(Figure 2B). Assessment of individual Multiparameter Cytotox-
icity assay parameters at later time points (d30) revealed a decrease
in nuclear intensity, and an increase in lysosomal mass/pH
(Figure S2Di,ii) indicative of early cellular apoptosis.
Lack of PINK1 sensitises neurons to mitochondrial-
mediated apoptosis
Using annexin V based flow cytometry we demonstrated that
SHSY5Y cells exposed to 60nM staurosporine (STS) for 24hrs
exhibited a significant reduction in the number of live cells in
PINK1 kd clones compared to controls (p=0.0002), as well as
higher levels of early apoptosis in PINK1 kd cells (p,0.0001), and
higher levels of total apoptosis in PINK1 kd cells (p=0.0002)
(Figure 3A). Preincubation of PINK1 kd cultures with 100 mMo f
the pan-caspase inhibitor Z-VAD-FMK 1hr prior to exposure with
STS abolished cell death and markers of early and late apoptosis
(data not shown).
To assess the pathway of STS-induced apoptosis, and how it is
sensitized in PINK1 kd cells, we used 0.75 mM STS for 4hrs, fixed
cells at different intervals and performed double immunofluores-
cence to assess the localisation of Bax and cytochrome c. Under
basal conditions Bax was observed in the cytosol and nucleus of
cells, cells but not in the mitochondria (demonstrated by the failure
of Bax to co-localise with the mitochondrial protein CoxV) whereas
cytochrome c was localised tothemitochondriaand showedoverlap
with Cox V staining. At 120 mins after addition of STS, some cells
in the PINK1 kd cultures appeared apoptotic with nuclear
fragmentation and condensation. In these cells, Bax staining co-
localised with Cox V, suggesting translocation of Bax to the
mitochondria from the cytosol in PINK1 kd cells undergoing
apoptoticstress(Figure 3B,a–h). Wefurtherconfirmedthis finding
using subcellular fractionation into mitochondrial and cytosolic
fractions and immunoblotting for Bax (data not shown). After 180
mins of exposure to STS, we observed several cells per field in
PINK1 kd cultures undergoing apoptosis as evidenced by nuclear
fragmentation and condensation. In these cells Cox V staining
demonstrated a loss of the tubular network of mitochondria,
mitochondrial fragmentation and abnormal clustering. In addition
to these nuclear and mitochondrial abnormalities, cytochrome c
was distributed diffusely in the cytoplasm of these cells, confirming
that it had been released from the mitochondria during apoptosis
(Figure 3B, i–p).
To further confirm the induction of apoptosis in PINK1 kd cells,
we assessed PINK1 kd cell lysates for active caspase-3 and PARP
cleavage at 90 minute intervals following exposure to 0.75 mM
STS. We demonstrate an increase in cleaved caspase 3, caspase 9,
and an increase in cleaved PARP in PINK1 kd cultures compared
to controls (Figure 3C). All these molecular events were activated
at earlier time points in the PINK1 kd cells compared to controls
suggesting an enhanced susceptibility to apoptosis via the
mitochondrial pathway.
We investigated whether a similar sensitivity to mitochondrial
apoptosis was evident in the human neurons as well as the
SHSY5Y cells. Both young and aged human PINK1 kd neurons
demonstrated enhanced sensitivity to STS and a higher induction
of mitochondrial apoptosis with increased expression of cleaved
caspase 3, caspase 9, and cleaved PARP (Figure 4 A, B). The
increased expression was confirmed using band densitometry. Of
note, the immunoreactive bands obtained using lysates from d43
neurons are less intense than those of young neurons due to the
reduced amount of material obtained from aged cultures.
Interestingly, activated caspase-3 was also detected in lysate from
PINK1 kd neurons treated with vehicle alone at d43 (Figure 4 B)
PINK1 Deficiency
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apoptosis in the absence of PINK1 in aged neurons.
PINK1 deficiency in neurons leads to mitochondrial
morphometric abnormalities
We investigated mitochondrial dysfunction in PINK1 kd cells
using live cell imaging of TMRM fluorescence. We found that
PINK1 deficiency leads to a reduction in mitochondrial
membrane potential (ym) in both SHSY5Y cells (data not shown)
and human neurons (Figure 5A). There was a mean reduction of
22% in the TMRM signal in PINK1 kd compared to controls
(p=0.046)(n=60 neurons/culture taken from 3 individual clones).
In addition, we found several lines of evidence suggesting
increased mitochondrial proliferation in both young and aged
human PINK1 kd neurons and in cortical PINK1 ko mouse
neurons. First, with human PINK1 kd neurons, we found an
increased uptake of the redox-sensitive dye, Mitotracker
CMXROS, suggesting an increase in mitochondrial mass
compared to controls (Figure 5B). Second, in PINK1 deficient
neurons we found a marked up-regulation of mitochondrial
OXPHOS complex subunits in aged human neurons as analysed
by Western blot (Figure 5D). There was no significant percentage
change in subunit expression between PINK1 kd and control
neurons at dd5. However, by dd43, expression of complex I, III
and V subunits had significantly increased in PINK1 kd neurons
by 107.8622.5 %, 125.165.4% and 233.8617.9% respectively,
as determined by band densitometry (p,0.01). Third, in vitro
assays showed an increase in the mitochondrial citrate synthase
activity within these cells (Figure 5C). We also found a significant
increase in mitochondrial mass using direct quantification of
mitochondria within individual neurons using transmission
electron microscopy (TEM) (Figure 5E). However, no parallel
Figure 2. Long term viability is reduced in PINK1 deficient neurons. A) Graph showing an increase in mean CI over time of human PINK1 kd
neurons compared to controls. Values shown are means6s.e.m of 3 control and 4 kd cultures, each measured in triplicate. B) Graph showing an
increase in mean CI over time of mouse embryonic cortical neuronal cultures taken from wild type and PINK1 knockout mice. Values shown are
means6s.e.m of wild type (PINK1+/+, n=2), and homozygote (PINK12/2, n=3) cultures each measured in triplicate. C,D,E) Comparison of
individual cell parameters assayed by the Cytotoxicity algorithm for aged human neurons (dd 52) with PINK1 kd compared to controls, including
mean nuclear size, mean nuclear intensity, plasma membrane permeability and lysosomal mass/pH. Values shown are means6s.e.m of 3 control and
4 kd cultures, each measured in triplicate. F) Histogram showing percentage apoptotic neuronal nuclei in aged control and PINK1 kd human neurons
under basal conditions. Values shown are mean percentages of neuronal nuclei that are pyknotic from 10 fields of view, 6sem from 3 independent
cultures.
doi:10.1371/journal.pone.0002455.g002
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biochemical techniques in neuronal models (data not shown).
Together these data suggest a compensatory increase in mito-
chondrial density in neurons lacking PINK-1. TEM analysis of
young and aged human neurons lacking PINK1 also revealed an
increase in the proportion of abnormal swollen mitochondria
within cells (Figure 5F,G) further supporting the hypothesis that
PINK1 functions to maintain mitochondrial integrity in neurons.
PINK1 deficiency in neurons is associated with an
increase in basal free radical production and decreased
steady state levels of glutathione
We utilised live cell imaging techniques using the redox-sensitive
dye dihydroethidium (HEt) which measures cytosolic ROS
production and the mitochondrial targeted variant of this dye,
Mitosox, to measure mitochondrial ROS production. (Figure 6A,B)
The basal rate of ROS generation was significantly increased in the
cytoplasm of PINK1 kd human neurons, showing a 2.79-fold
increase in basal rate of fluorescence increase (mean=279611.3%,
n=189 cells,p,0.001). Stimulationofneuronswith 50 mMKClto
transiently raise [Ca
2+]c, increased the rate of ROS production in
control cells, which showed a 3.2 fold increase in the rate of HEt
fluorescence (from basal 100% to 321619.3% while the response in
PINK1 kd neurons was much smaller (from 279611.3% to
300.1614.7%, where 100%- basal rate of ROS in control neurons)
(Figure 6 C,D). We demonstrated a higher basal rate of
mitochondrial superoxide production in PINK1 kd neurons
compared to controls (the rate of increase of MitoSOX fluorescence
was 2.1-fold higher in PINK1 kd neurons (mean=212614.1%,
p,0.001). The complex I inhibitor, rotenone caused a smaller
proportional increase in superoxide production in PINK1 kd
(210.2% to 255.469.9%) compared to controls (100% to
212.1611.6%) due to the higher basal levels of ROS generation,
although the absolute rate of ROS generation in response to
rotenone was higher in PINK1 kd neurons. (Figure 6A,B)
In addition to measuring ROS production we assayed the
antioxidant defense mechanisms by analysing glutathione levels in
young (dd5) and aged (dd43) human neurons. (Figure 6Ei, ii).
We demonstrate a significant reduction in the total levels of
glutathione (reduced+oxidised) in PINK1 kd cells, implying an
impairment of glutathione synthesis. A decrease in the ratio of
reduced:oxidised glutathione was not found.
Aged midbrain derived neurons deficient in PINK1
contain lysosomal aggregates
In addition to morphological mitochondrial abnormalities in
aged human PINK1 kd neurons, we also found large intracyto-
Figure 3. Apoptosis pathway in PINK1 kd SHSY5Y cells. A) Histogram showing a significant increase in apoptosis in PINK1 kd SHSY5Y cells in
response to STS compared to controls. Cells were incubated with 60nM STS or vehicle overnight prior to analysis of annexinV/PI binding by FACS.
Values represent mean of 20,000cells/well, of duplicate wells of 3 clones across 5 independent experiments6s.e.m. B) Panel a-h shows double
immunofluorescence using Bax and Cox V antibodies in SHSY5Y cells treated with 0.75 mM STS. At 120 minutes, Bax (green) is seen in the cytoplasm
and nucleus of control cells, with no overlap with a mitochondrial marker Cox V (red). In PINK1 kd cultures, arrows highlight two cells with evidence of
nuclear condensation suggestive of apoptosis. In these cells, Bax immunofluorescence overlaps with Cox V immunofluorescence indicating Bax
localisation in the mitochondria. Panel l-p shows double immunofluorescence using cytochrome c and Cox V antibodies. At 180 minutes, there is
overlap of cytochrome c (green) and Cox V (red) in control cells indicating cytochrome c localisation in the mitochondria. However in PINK1 kd cells
arrows indicate several apoptotic cells with diffuse cytosolic cytochrome c, indicating translocation from mitochondria to cytoplasm. Images are
representative of two independent experiments with 3 clones. Images were acquired by obtaining z-stacks through cells at x63 oil objective. C)
Western blot showing increased apoptosis on exposure to STS in PINK1 kd SHSY5Y cells. Cells were incubated with 0.75 mM mM STS for 6hrs. Cleaved
caspase 9, cleaved caspase 3, and PARP expression is increased at earlier time points in PINK1 kd cells than in controls.
doi:10.1371/journal.pone.0002455.g003
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reminiscent of autophagosomes, at a frequency of approximately
30% (Figure 7A). To determine whether these structures were
lysosomal in origin, we applied the acidophilic Lysotracker dye to
aged cultures and found this dye was taken up into these distinctive
aggregates, which were considerably larger and more numerous in
PINK1 kd neurons compared to controls (Figure 7B).
The phenotypes observed in the different cell models of PINK1
loss-of-function are summarised in Table 1.
Discussion
The aim of this study was to further elucidate the function of
PINK1 in the prevention of DAergic degeneration seen in
Parkinson’s disease. We produced stable knockdown models of
PINK1 using small interfering RNAs in two complementary cell
lines–human neuroblastoma SHSY5Y and a novel human NSC
line capable of high levels of DAergic differentiation. In addition,
we used primary neuronal cultures from PINK1 knockout mice to
corroborate our findings and control for potential non-specific
effects of RNAi. Human neurons are generated from immortalised
human fetal ventral mesencephalic neural stem cells (NSCs) which
maintain a stable karyotype in culture, stable growth rates and
readily differentiate into function neurons–thus providing advan-
tages over commonly used ‘‘cancer’’ cell lines [39]. Differentiated
NSCs cultures contain a high percentage of DAergic neurons
which express typical neuronal markers and display characteristic
action potentials. The use of stable RNAi allowed us to study the
molecular changes occurring in human DAergic neurons during
the process of ageing in a PINK1 null background. Our model
therefore represents an in vitro system highly relevant to human
PD, which is both progressive and age-dependent.
PINK1 expression in dopaminergic neurons
We found that PINK1 expression is up-regulated ,100 fold
during differentiation of human NSCs into human neurons,
suggesting that PINK1 has an important function in differentiated
neurons. However, it is important to note that PINK1 did not
affect differentiation into the DAergic phenotype. This suggests
PINK1 is not necessary for development which is in-line with the
progression of the PINK1 mutation onset of PD. Endogenous
PINK1 was expressed within soma and neurites of post-mitotic
dopaminergic neurons, although it was not expressed exclusively
in these subtypes. This is consistent with previous reports which
show endogenous PINK1 expression in both neurons and glia
throughout brain [21,24]. PINK1 expression in neurons was
highest within mature processes, where its expression may be most
critical.
PINK1 deficiency and long term survival
A major finding in our study was the reduction in long term
viability of human and mouse neurons deficient in PINK1. To our
knowledge this is the first age-dependent phenotype reported for
any in vitro cell model of PD. A progressive phenotype has been
reported in PINK1 knockout Drosophila models, attributable to an
increased level of apoptosis, but so far not in mammalian models
[32,34]. We observed significant age-dependent increases in cell
death and apoptosis in mammalian neurons which provide a
mechanism for the progressive phenotype seen in both sporadic
and genetic forms of PD which have up until now been difficult to
recapitulate in vitro.
PINK1deficiency sensitises neurons to mitochondrial
apoptosis
An increase in apoptosis has been previously reported in
SHSY5Y cells following transient RNAi-mediated PINK1 kd, and
in fibroblasts taken from patients with compound heterozygous
PINK1 mutations [35,37]. Interestingly, no basal increase in cell
death and apoptosis was observed with PINK1 deficient
differentiated human neurons or primary mouse neurons at early
time points. However, molecular differences do exist between
control and PINK1 kd cells at this early stage, specifically in their
ability to handle mitochondrial stress. We find that PINK1
deficient cells are acutely sensitive to the toxin STS, which triggers
mitochondrial apoptosis via opening of the mitochondrial
permeability transition pore (MPTP) and subsequent cytochrome
c release. In SHSY5Y cells lacking PINK1, Bax translocation to
Figure 4. Apoptosis in PINK1 kd human neurons. Western blots
showing increase in basal (2) and STS-induced (+) cleaved caspase 3,
cleaved caspase-9 (two bands ,36 and ,32 kDa) and cleaved PARP
without PINK1 in young (A) (dd5) and aged (B) (dd43) human control
and PINK1 kd neuronal cultures. Each lane is a sample from three
pooled independent culture lysates. The lowest bands are immunore-
active degradation products which run at the foot of an SDS-PAGE gel.
doi:10.1371/journal.pone.0002455.g004
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PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2455Figure 5. Mitochondrial abnormalities in PINK1 deficient neurons. A) PINK deficiency leads to a reduced basal mitochondrial membrane
potential (ym) in young PINK1 kd neurons compared to controls, analysed using TMRM fluorescence. Values are mean percentages of the control
cultures (normalised to 100%) from three independent experiments. B) Histogram showing increased uptake of the redox sensitive dye
MitotrackerRed in human PINK1 kd neuronal cultures compared to controls at early and later time points. Values represent means6sem of 3 control
or three PINK1 kd cultures (measured in triplicate). C) Histogram showing increased citrate synthase (CS) activity in aged (d30) PINK1 kd human
neurons compared to controls. Values represent means6sem from three independent cultures. D) Western blot showing expression of mitochondrial
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occurs earlier than in controls, and results in elevated levels of
caspase activation (caspase-3 and caspase-9). In turn, increased
levels of PARP cleavage and nuclear fragmentation are observed
in PINK1 kd cells. Our findings are in line with previous reports
demonstrating that PINK1 over-expression protects cells from
STS-induced apoptosis [35] and transient RNAi-mediated PINK1
kd sensitises cells to various stressors [37,38,42,43]. Our findings
confirm the requirement of PINK1 within human neurons for the
regulation of mitochondrial permeability transition, and preven-
tion of caspase-3 mediated neuronal apoptosis. Our model shows
some similarities to toxin based models of PD: the administration
of MPTP to mice results in dopaminergic neuronal loss mediated
by Bax translocation to the mitochondria, cytochrome c release,
and activation of caspase 9 and caspase 3. In corroboration, over-
expression of PINK1 in the SN of rats protects against the effects
of MPTP [38]. In the MPTP model, the sensitivity to Bax-
mediated apoptosis is determined by high levels of ROS (resulting
from MPTP induced complex 1 deficiency) increasing the soluble
pool of cytochrome c in the intermembrane space that may be
released on stimulation by Bax. [44,45] In our model, PINK1
deficiency is also associated with high levels of mitochondrial ROS
production and thus the increased sensitivity to mitochondrial
apoptosis may operate by a similar mechanism.
PINK1 deficiency causes loss of mitochondrial membrane
potential (ym)
Mitochondrial dysfunction is strongly implicated in the
pathogenesis of PD, either as a cause or downstream hallmark
of dopaminergic degeneration [46]. PINK1 is targeted to
mitochondria where it is has been proposed to maintain
mitochondrial membrane potential (ym), the driving force behind
oxidative phosphorylation and ion transportation. Over-expres-
sion of wild type PINK1 in cell lines was found to protect cells
from membrane depolarisation in response to proteasomal stress
[27,47]. Using live imaging techniques we show that PINK1
deficiency causes a reduction in the basal ym in human neurons,
implicating a role for PINK1 in the maintenance of membrane
potential, even in the absence of stress. This is a significant finding
as mitochondrial potential is critical for the synthesis of ATP
through the dissipation of the transmembrane proton gradient.
ATP availability is critical for cellular anabolism and importantly
for neurons, maintaining a resting plasma membrane potential for
cell excitability. A reduced proton gradient would explain
decreased ATP levels in PINK1 fly knockout models [32,34]
and it would be interesting to investigate whether this is due to a
reduced ym in vivo.
PINK1, ROS generation and glutathione levels
One important sequelae of mitochondrial dysfunction is
increased generation of reactive oxygen species, which in turn
can cause oxidative stress and damage to macromolecules within
cells [11]. This damage extends to the mitochondrial respiratory
components themselves, compromising function further. Evidence
of oxidative stress and damage to proteins, lipids and nucleic acids
has been found in the substantia nigra of sporadic PD patients and
more recently, in fibroblasts from patients carrying PINK1
mutations [48]. We show here that in the absence of PINK1,
ROS generation in both mitochondria and cytoplasm is increased,
even in young human neurons. PINK1 knockout flies demonstrate
increased sensitivity to oxidative stress [31,33] and increased ROS
generation and oxidative stress is similarly found in animal models
of parkin and DJ-1 loss-of-function [49–52]. Hence ROS
generation and elevated oxidative stress appears to be a unifying
cellular phenotype in recessive Parkinsonism. This is the first
demonstration that increased ROS production occurs early in a
mammalian model of PD prior to neuronal stress and apoptosis,
and hence suggests that it has an important role in the
pathogenesis of neuronal dysfunction and death.
PINK1 may exert its protective effect on ym and the prevention
of ROS generation via phosphorylation of Tumor-necrosis factor
associated protein-1 (TRAP1). TRAP1 (Hsp75) is an ATP-binding
molecular chaperone co-localises with PINK1 in mitochondria,
and is phosphorylated by PINK1 in vitro [43]. Silencing of TRAP1
in tumor cells also causes mitochondrial swelling, loss of ym, rapid
increase in intracellular ROS generation and release of cyto-
chrome C, identical to the effects of PINK1 knockdown [43,53].
Rescue experiments placed TRAP1 downstream of PINK1, with
phosphorylation of TRAP1 required for its protective activity,
which indirectly prevents the release of cytochrome C and ROS
generation in response to apoptogenic agents such as hydrogen
peroxide. The role of a putative PINK1-TRAP1 interaction in
dopaminergic neurons has yet to be investigated, but could
provide a key to selective degeneration of these cells if heavily
utilised as a protective pathway during stress.
The primary mechanism for detoxification of ROS in the
cytoplasm is the oxidation of reduced glutathione (GSH), which is
regenerated harmlessly to the reduced species by the flavoenzyme
glutathione reductase. We show that there is a significant decrease
in steady state levels of total glutathione in primary human
neurons lacking PINK1, which is likely to greatly impair their
antioxidant defences. Evidence for decreased total GSH levels in
the brains of patients with idiopathic PD has been widely reported
and may occur as a result of decreased GSH synthesis, which is
ATP dependent and thus compromised as a result of failing
membrane potential [54]. Chronic inhibition of glutathione
synthesis in dopaminergic neurons in vitro using buthionone-S-
sulfoximime (BSO) reduced long term neuronal viability [55].
Numerous studies in rodents have demonstrated that glutathione
deficiency by BSO administration results in mitochondrial swelling
with vacuolization and rupture of the cristae and mitochondrial
membranes seen by EM [56]. This may explain our observations
of altered mitochondrial morphology in PINK1 deficient human
neurons (see below). The importance of glutathione in recessive
PD has already been explored: depleting parkin null flies of
subunits in young (D5) and aged (D43) human neurons lacking PINK1 compared to controls. Note the increase in complex subunit expression in aged
neurons lacking PINK1. Replicate lanes of pooled samples from three independent cultures are shown. Expression of OXPHOS subunits C-I-20 (ND6),
C-II-30 (FeS), C-III-Core-2 and C-V-a is shown. b-actin; loading control. E) Graph showing significantly increased mean number of mitochondria/cell in
aged PINK1 kd human neurons compared to controls, as quantified by TEM analysis. Histogram shows mean number mitochondria per cell 6sem
averaged from at least 50 cells. F) Increased frequency of abnormal mitochondria of aged human PINK1 kd neurons compared to controls, quantified
using TEM. Histogram shows mean frequency of abnormal mitochondria (per total number mitochondria in each cell) 6sem, n=50 cells. G) TEM
images showing abnormal mitochondria (arrowheads) within aged (d47) human neurons lacking PINK1 (panel b, and at higher magnification in d)
compared to control neurons (panel a). There are increased numbers of mitochondria within cells lacking PINK1 (panel b) compared to controls
(panel A) and a higher proportion of mitochondria in PINK1 kd neurons appear swollen with disorganised christae (panels c, d). Scale bar in a,b;
10 mM, c = 500 nM.
doi:10.1371/journal.pone.0002455.g005
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PLoS ONE | www.plosone.org 11 June 2008 | Volume 3 | Issue 6 | e2455Figure 6. Free Radical Production in PINK1 knockdown neurons. A) and (B) demonstrate a higher basal production of ROS production in
mitochondria of PINK1 kd neurons compared to controls. Image in Figure 6A confirms mitochondrial localisation of Mitosox probe in neurons.
Inhibition of complex 1 with rotenone induced a significant increase of ROS production in control cells. Inhibition of complex 1 in PINK1 kd cells
slightly increased ROS production which is still higher than rotenone induced ROS production in control mitochondria. The basal rate of Mitosox
fluorescence in control cells was taken as 100%. C) Shows an increase in the rate of HEt fluorescence in response to 50 mM KCL in control neurons. D)
PINK1 kd neurons have higher basal rates of cytosolic ROS production compared to control neurons. Stimulation using KCl results in an increase in
ROS production which is more marked in control than PINK1 kd neurons. E) Histogram showing decreased reduced and total glutathione
concentrations in young (dd5 i) and in aged (dd43 ii) and human PINK1 kd neurons compared to controls. Values represent means 6sem from
triplicates of three independent samples.
doi:10.1371/journal.pone.0002455.g006
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PLoS ONE | www.plosone.org 12 June 2008 | Volume 3 | Issue 6 | e2455Figure 7. Abnormal lysosomal morphology in PINK1 kd neurons. A) TEM images of vesicular aggregates within surviving aged human
neurons lacking PINK1 at dd47. A control neuron is shown in panel A. Panels b-d show aggregates in PINK1 kd neurons, panel c is an aggregate
enlarged from b. Scale bars; a, b; 20 mM, d; 2 mM. B) Immunofluorescence images of aged (dd47) control human neurons (panels a-c) and PINK1 kd
neurons (d–f) showing lysosomal morphology (red staining; panels b and e). Nuclei are shown in blue (panels a and d), merged images presented in
panels c and f. Large and multiple aggregates seen only in PINK1 kd neurons are positive for the dye Lysotracker (panel d). ,Scale bar = 20 mM
doi:10.1371/journal.pone.0002455.g007
Table 1. Summary of the phenotypes observed with PINK1 deficiency in the different cell models used.
Model
PINK1
deficiency
Reduced
viability
Sensitivity to
apoptosis
Mitochondria
dysfunction Oxidative stress
Lysosomal
dysfunction
SHSY5Y human shRNA Age-related Basal STS-induced QDym N/A N/A
Midbrain neurons
human
shRNA Age-related Basal STS-induced QDym Altered mitochondrial
morphology
qROS Q total
glutathione
qautophago-lysosomes
q lysotracker uptake
Cortical neurons
mouse
Trans-genic Age-related Basal N/A N/A q lysotracker uptake
N/A = not assessed
doi:10.1371/journal.pone.0002455.t001
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ative phenotype [57]. Conversely, re-introduction of GST was
found to rescue the mitochondrial swelling and neuronal loss in
parkin knockouts [58]. Clearly, there exists a complex interrela-
tionship between glutathione levels, respiratory chain impairment,
mitochondrial morphology, and cell viability within neurons which
both PINK1 and parkin co-operate [32].
Altered mitochondrial integrity and proliferation
Interestingly a disrupted mitochondrial morphology was seen in
aged human neurons lacking PINK1. Neuronal mitochondria
appeared enlarged, with disrupted cristae and greatly reduced
matrix volume. This finding corroborates the striking muscle
phenotype in PINK1 and parkin knockout fly models, where
myofibrils contain vacuolated, swollen and dysmorphic mitochon-
dria, with disorganised christae [31,32,34]. Enlarged mitochondria
were also seen in surviving dopaminergic neurons, the frequency
of which increased with age [32]. Using genetic complementation
experiments PINK1 was subsequently shown to function ‘up-
stream’ of parkin to regulate mitochondrial integrity [32].
Recently, it was found that loss-of-function of the mitochondrial
fission-promoting component Drp1, caused lethality in PINK1 or
parkin knockout flies [59]. Conversely, over-expression of Drp1 or
mutations in mitochondrial fusion-promoting proteins (Mitofusin2
and OPA1) suppressed the PINK1 and parkin null phenotype.
These experiments suggest that these PD genes co-operate to
regulate mitochondrial dynamics and that mitochondrial fission
(splitting) is stimulated in response to inactivation of the PINK1-
parkin pathway.
We provide interesting evidence for mitochondrial proliferation
in PINK1 knockdown neurons, including increases in mean
mitochondrial number per neuron, increased Mitotracker uptake,
enhanced expression of respiratory chain complex subunits and
elevated citrate synthase activity. Despite an increase in mass, no
significant change in respiratory chain activity was detected in
neurons lacking PINK1, implying that oxidative phosphorylation
may be impaired in the increased numbers of mitochondria in
these cells. It is established that increased levels of intracellular
ROS may mediate changes in mitochondrial abundance and
mtDNA copy number which occur during the ageing process [60].
The oxidative stress induced proliferation of mitochondria may
initially be beneficial to compensate for dysfunctional mitochon-
dria, and to supply ATP needed for cell survival. However
increased numbers of mitochondria will also result in a further
excess of ROS, which in the presence of insufficient antioxidant
defense mechanisms, will produce more oxidative damage to cells.
Increased oxidative damage will render neurons susceptible to
death by apoptosis from mitochondrial membrane permeabilisa-
tion and cytochrome c release, or by necrosis due to insufficient
ATP production. An increase in mitochondrial proliferation has so
far not been reported in any other PD model.
PINK1 deficiency and lysosomes
We also report here a novel phenotype in the surviving neurons
of PINK1 deficient neurons which resembles the pathology
observed in lysosomal storage diseases. Large intracellular bodies
comprised of multivesicular ‘aggregates’ were detected in ageing
PINK1 kd neurons, which were lysosomal in nature. PINK1 has
not previously been implicated in lysosomal dysfunction but
endogenous PINK1 expression has been detected in microsomes
[35]. Lysosomes are present within autophagosomes, the multi-
lamellar bodies responsible for proteolytic degradation of macro-
molecules and thought to be crucial in the clearance of
amyloidogenic proteins such as a-synuclein and huntingtin [61].
Autophagy involves the non-selective degradation of proteins and
organelles by lysosomes. However selective autophagy for certain
damaged organelles such as mitochondria may occur in response
to ROS. Moreover it has been proposed that mitochondria may
act as a major source of the ROS signal required to activate
autophagy. In our model of PINK1 deficiency we see an increase
in autophagolysosomes suggesting an upregulation of autophagy.
This may be occurring as a response to remove oxidatively
damaged proteins and/or structurally abnormal mitochondria.
The concurrent increase in cytosolic and mitochondrial ROS
production may act as a signal for this process [62]. The lysosomal
pathology we find in neurons resembles that seen in SHSY5Y cells
over-expressing mutant b-synuclein protein [63]. b-synuclein is
thought to be neuroprotective by interacting with and preventing
the formation of a-synuclein inclusions. Pharmacological preven-
tion of autophagy exacerbated cell death and a-synuclein toxicity,
suggesting that they may fulfil a protective function in neurons.
Enhancing formation of lysosomal clearance mechanisms in PD
may therefore be a viable therapeutic strategy.
In summary, to study the role of PINK1 in PD, we have
generated models of PINK1 loss of function in human and mouse
neurons. PINK1 is up-regulated during neuronal differentiation
and plays a major role in the neuroprotection of mature neurons.
Neurons that lack PINK1 function are prone to apoptosis via the
intrinsic mitochondrial apoptosis pathway. Moreover loss of
PINK1 function results in increased levels of oxidative stress and
reduced mitochondrial membrane potential, suggesting that
mitochondrial dysfunction directly leads to the increased suscep-
tibility to apoptosis. Further characterisation of the molecular
events within mitochondria that lack PINK1 will enable a better
understanding of the pathophysiologic mechanisms that cause the
phenotype of PINK1 loss-of-function. Persistent mitochondrial
dysfunction over time ultimately results in structural changes of the
mitochondria which are reminiscent of PINK1 knockout fly
models, but to date have not been detected in mammalian models.
To our knowledge this is the first study to provide a functional
role for PINK1 in human neurons, and specifically midbrain
derived neurons. Modelling human neurodegenerative disease
may only be successfully achieved through recapitulation of the
ageing process. Under these circumstances we find an age-specific
phenotype for loss of PINK1 function. This provides unique
insights into the pathogenesis of sporadic PD in which the
phenotype of oxidative stress, mitochondrial dysfunction and
neuronal apoptosis has been well established. Further it suggests a
convergence of the molecular pathways of PINK1-associated PD
and sporadic PD.
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DOC)
Figure S1 A) Graph showing the increase in mRNA of different
markers of dopamine neurons following differentiation of NSCs to
neurons, using the pre-D method. Expression of TH, DAT,
lmx1a, and Nurr1 are significantly elevated upon differentiation.
Levels are normalized to housekeeping gene ATPB5, and shown
relative to fetal brain tissue expression. B) Graph showing the
effects of four different shRNA constructs on PINK1 gene
expression in SHSY5Y cells. Values are mean RQs of five
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PLoS ONE | www.plosone.org 14 June 2008 | Volume 3 | Issue 6 | e2455clones6s.e.m. Construct 1; sequence 1029, Construct 2; sequence
2194. Construct 3; 780, Construct 4; lamin AC. C) Graph showing
knockdown effect of shRNA construct 1 (1029) on PINK1 gene
expression in individual NSC clones normalized to expression
levels with vector only. Values are mean RQ; plus and minus error
bars represent maximum and minimum possible RQ value. D)
Western blot showing endogenous PINK1 expression in primary
cortical neurons in either wild type (WT), Heterozygote (Ht) or
PINK1 knockout (KO) mouse primary cortical neurons. Anti-
PINK1 (Novus) was used to detect PINK expression; b-actin levels
are shown as loading control.
Found at: doi:10.1371/journal.pone.0002455.s003 (0.89 MB TIF)
Figure S2 A) Histogram showing no significant increase in basal
levels of apoptosis in PINK1 kd human NSCs compared to control
cells after 24 h in culture. Levels of AnnexinV/PI staining were
quantified using FACS. Values represent means of 3 independent
experiments measured in triplicate6sem. B) Histogram demon-
strating significant differences in live cell number, early apoptosis
(annexin V only) and total apoptosis (annexin V+PI) in PINK1 kd
SHSY5Y cells compared to controls. Cells were cultured for
96 hours before assaying using annexin V based FACS. Values
represent mean values of 3 clones plated in duplicate and 20,000
cells measured per well6sem C) Double immunofluorescnece of
primary embryonic mouse neuronal cultures using MAP2 (green),
GFAP (red) and Hoechst (blue). Scale bar = 20 mM. D)
Comparison of individual cell parameters assayed by the
Cytotoxicity algorithm for aged PINK1 KO mouse cortical
neurons (day 30) compared to wild type controls, including mean
nuclear size, mean nuclear intensity and lysosomal mass/pH.
Values shown are means6s.e.m of 2 wild type and 3 KO cultures,
each measured in triplicate.
Found at: doi:10.1371/journal.pone.0002455.s004 (4.00 MB TIF)
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